In response to AZD8055 treatment for 21 days, tumor volume and burden were significantly reduced (Fig. 3), while the expression of pACC, the direct target of AMPK, and pAMPK were elevated, and expression of pS6, the target of S6 kinase, was markedly reduced, compared with other treatments. The gene discussed is TAS2R63P; the disease is neoplasm.